使用α-突触核蛋白种子扩增试验评估帕金森病进展标志物计划队列参与者的异质性:一项横断面研究
本研究基于帕金森病进展标志物计划(PPMI)多中心队列的横断面分析,评估α-突触核蛋白种子扩增试验(SAA)对帕金森病的诊断性能。纳入1123名参与者,帕金森病灵敏度为87.7%(95%CI 84.9-90.5),健康对照特异度为96.3%(93.4-99.2)。SAA在典型嗅觉缺失的散发性帕金森病中灵敏度达98.6%,并可在前驱期个体中检测到阳性结果。
要点
- α-突触核蛋白SAA诊断帕金森病灵敏度87.7%,健康对照特异度96.3%。
- 典型嗅觉缺失的散发性帕金森病灵敏度98.6%,LRRK2帕金森病为67.5%。
- 前驱期RBD或嗅觉减退者86%阳性,非 manifesting携带者8%阳性。
核心结论
- α-突触核蛋白SAA能以高灵敏度和特异度对帕金森病进行分类,提供分子异质性信息,并可在诊断前检测前驱期个体。
研究设计与样本
- 横断面分析,基于PPMI队列纳入1123名参与者,来自全球33个学术神经科门诊,入组时间为2010年7月7日至2019年7月4日。
主要发现
- 帕金森病灵敏度为87.7%(95%CI 84.9-90.5),健康对照特异度为96.3%(93.4-99.2)。
- 典型嗅觉缺失的散发性帕金森病灵敏度为98.6%(96.4-99.4),LRRK2帕金森病为67.5%(59.2-75.8),无嗅觉缺失的散发性帕金森病为78.3%(69.8-86.7)。
- LRRK2变异且嗅觉正常者阳性率为34.7%(21.4-48.0)。
- 前驱期RBD或嗅觉减退者中44/51(86%)阳性(嗅觉减退16/18,RBD 28/33);非 manifesting携带者中25/310(8%)阳性(LRRK2 14/159 [9%],GBA 11/151 [7%])。
关键数值与推荐
- 帕金森病灵敏度87.7%(95%CI 84.9-90.5),健康对照特异度96.3%(93.4-99.2)。
- 典型嗅觉缺失的散发性帕金森病灵敏度98.6%(96.4-99.4),LRRK2帕金森病67.5%(59.2-75.8),无嗅觉缺失的散发性帕金森病78.3%(69.8-86.7)。
- LRRK2变异且嗅觉正常者阳性率34.7%(21.4-48.0)。
- 前驱期RBD或嗅觉减退者阳性率86%(44/51),非 manifesting携带者阳性率8%(25/310)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Emerging evidence shows that α-synuclein seed amplification assays (SAAs) have the potential to differentiate people with Parkinson's disease from healthy controls. We used the well characterised, multicentre Parkinson's Progression Markers Initiative (PPMI) cohort to further assess the diagnostic performance of the α-synuclein SAA and to examine whether the assay identifies heterogeneity among patients and enables the early identification of at-risk groups. METHODS: This cross-sectional analysis is based on assessments done at enrolment for PPMI participants (including people with sporadic Parkinson's disease from LRRK2 and GBA variants, healthy controls, prodromal individuals with either rapid eye movement sleep behaviour disorder (RBD) or hyposmia, and non-manifesting carriers of LRRK2 and GBA variants) from 33 participating academic neurology outpatient practices worldwide (in Austria, Canada, France, Germany, Greece, Israel, Italy, the Netherlands, Norway, Spain, the UK, and the USA). α-synuclein SAA analysis of CSF was performed using previously described methods. We assessed the sensitivity and specificity of the α-synuclein SAA in participants with Parkinson's disease and healthy controls, including subgroups based on genetic and clinical features. We established the frequency of positive α-synuclein SAA results in prodromal participants (RBD and hyposmia) and non-manifesting carriers of genetic variants associated with Parkinson's disease, and compared α-synuclein SAA to clinical measures and other biomarkers. We used odds ratio estimates with 95% CIs to measure the association between α-synuclein SAA status and categorical measures, and two-sample 95% CIs from the resampling method to assess differences in medians between α-synuclein SAA positive and negative participants for continuous measures. A linear regression model was used to control for potential confounders such as age and sex. FINDINGS: This analysis included 1123 participants who were enrolled between July 7, 2010, and July 4, 2019. Of these, 545 had Parkinson's disease, 163 were healthy controls, 54 were participants with scans without evidence of dopaminergic deficit, 51 were prodromal participants, and 310 were non-manifesting carriers. Sensitivity for Parkinson's disease was 87·7% (95% CI 84·9-90·5), and specificity for healthy controls was 96·3% (93·4-99·2). The sensitivity of the α-synuclein SAA in sporadic Parkinson's disease with the typical olfactory deficit was 98·6% (96·4-99·4). The proportion of positive α-synuclein SAA was lower than this figure in subgroups including LRRK2 Parkinson's disease (67·5% [59·2-75·8]) and participants with sporadic Parkinson's disease without olfactory deficit (78·3% [69·8-86·7]). Participants with LRRK2 variant and normal olfaction had an even lower α-synuclein SAA positivity rate (34·7% [21·4-48·0]). Among prodromal and at-risk groups, 44 (86%) of 51 of participants with RBD or hyposmia had positive α-synuclein SAA (16 of 18 with hyposmia, and 28 of 33 with RBD). 25 (8%) of 310 non-manifesting carriers (14 of 159 [9%] LRRK2 and 11 of 151 [7%] GBA) were positive. INTERPRETATION: This study represents the largest analysis so far of the α-synuclein SAA for the biochemical diagnosis of Parkinson's disease. Our results show that the assay classifies people with Parkinson's disease with high sensitivity and specificity, provides information about molecular heterogeneity, and detects prodromal individuals before diagnosis. These findings suggest a crucial role for the α-synuclein SAA in therapeutic development, both to identify pathologically defined subgroups of people with Parkinson's disease and to establish biomarker-defined at-risk cohorts. FUNDING: PPMI is funded by the Michael J Fox Foundation for Parkinson's Research and funding partners, including: Abbvie, AcureX, Aligning Science Across Parkinson's, Amathus Therapeutics, Avid Radiopharmaceuticals, Bial Biotech, Biohaven, Biogen, BioLegend, Bristol-Myers Squibb, Calico Labs, Celgene, Cerevel, Coave, DaCapo Brainscience, 4D Pharma, Denali, Edmond J Safra Foundation, Eli Lilly, GE Healthcare, Genentech, GlaxoSmithKline, Golub Capital, Insitro, Janssen Neuroscience, Lundbeck, Merck, Meso Scale Discovery, Neurocrine Biosciences, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, VanquaBio, Verily, Voyager Therapeutics, and Yumanity.
引用
- Siderowf A, Concha-Marambio L, Lafontant DE, et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023. PMID: 37059509. doi:10.1016/S1474-4422(23)00109-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。